Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Neonatal vancomycin continuous infusion: still a confusion?

Gwee A, Cranswick N, Metz D, Coghlan B, Daley AJ, Bryant PA, Curtis N.

Pediatr Infect Dis J. 2014 Jun;33(6):600-5. doi: 10.1097/INF.0000000000000243. Review.

PMID:
24378952
2.

Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring.

Zhao W, Lopez E, Biran V, Durrmeyer X, Fakhoury M, Jacqz-Aigrain E.

Arch Dis Child. 2013 Jun;98(6):449-53. doi: 10.1136/archdischild-2012-302765. Epub 2012 Dec 19.

PMID:
23254142
3.

The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.

Waineo MF, Kuhn TC, Brown DL.

J Clin Pharm Ther. 2015 Jun;40(3):259-65. doi: 10.1111/jcpt.12270. Epub 2015 Apr 11. Review.

PMID:
25865426
4.

Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.

Mehrotra N, Tang L, Phelps SJ, Meibohm B.

Pharmacotherapy. 2012 May;32(5):408-19. doi: 10.1002/j.1875-9114.2012.01029.x. Epub 2012 Apr 9.

PMID:
22488303
5.

Vancomycin prescription in neonates and young infants: toward a simplified dosage.

Oudin C, Vialet R, Boulamery A, Martin C, Simon N.

Arch Dis Child Fetal Neonatal Ed. 2011 Sep;96(5):F365-70. doi: 10.1136/adc.2010.196402. Epub 2011 Mar 6.

PMID:
21378399
6.

Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia.

Hochart C, Berthon C, Corm S, Gay J, Cliquennois M, Tricot S, Alfandari S.

Med Mal Infect. 2011 Dec;41(12):652-6. doi: 10.1016/j.medmal.2011.09.014. Epub 2011 Nov 6.

PMID:
22056376
7.

Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule.

Plan O, Cambonie G, Barbotte E, Meyer P, Devine C, Milesi C, Pidoux O, Badr M, Picaud JC.

Arch Dis Child Fetal Neonatal Ed. 2008 Nov;93(6):F418-21. doi: 10.1136/adc.2007.128280. Epub 2008 May 1. Erratum in: Arch Dis Child Fetal Neonatal Ed. 2009 Jan;94(1):F78.

PMID:
18450803
8.

Vancomycin population pharmacokinetics in neonates.

de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN.

Clin Pharmacol Ther. 2000 Apr;67(4):360-7.

PMID:
10801244
9.

Continuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients.

Hong LT, Goolsby TA, Sherman DS, Mueller SW, Reynolds P, Cava L, Neumann R, Kiser TH.

J Crit Care. 2015 Oct;30(5):1153.e1-6. doi: 10.1016/j.jcrc.2015.06.012. Epub 2015 Jun 23.

PMID:
26239323
10.

Observational clinical study on the effects of different dosing regimens on vancomycin target levels in critically ill patients: Continuous versus intermittent application.

Tafelski S, Nachtigall I, Troeger U, Deja M, Krannich A, Günzel K, Spies C; ABx Study Group.

J Infect Public Health. 2015 Jul-Aug;8(4):355-63. doi: 10.1016/j.jiph.2015.01.011. Epub 2015 Mar 17.

11.

Evaluation of a pediatric continuous-infusion vancomycin therapy guideline.

McKamy S, Chen T, Lee M, Ambrose PJ.

Am J Health Syst Pharm. 2012 Dec 1;69(23):2066-71. doi: 10.2146/ajhp120072.

PMID:
23172265
12.

Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy.

Akers KS, Cota JM, Chung KK, Renz EM, Mende K, Murray CK.

J Burn Care Res. 2012 Nov-Dec;33(6):e254-62. doi: 10.1097/BCR.0b013e31825042fa.

PMID:
22878490
13.

Pharmacokinetics and dose requirements of vancomycin in neonates.

Grimsley C, Thomson AH.

Arch Dis Child Fetal Neonatal Ed. 1999 Nov;81(3):F221-7.

14.

Design and prospective validation of a dosing instrument for continuous infusion of vancomycin: a within-population approach.

van Maarseveen EM, Bouma A, Touw DJ, Neef C, van Zanten AR.

Eur J Clin Pharmacol. 2014 Nov;70(11):1353-9. doi: 10.1007/s00228-014-1742-6. Epub 2014 Aug 30.

PMID:
25168621
15.

Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study.

Blot S, Koulenti D, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, Roberts JA.

Crit Care. 2014 May 15;18(3):R99. doi: 10.1186/cc13874.

16.

Vancomycin continuous infusion as prophylaxis for vascular surgery.

Payne CJ, Carmichael SJ, Stearns AT, Kingsmore DB, Byrne DS, Binning AR.

Ther Drug Monit. 2009 Dec;31(6):786-8. doi: 10.1097/FTD.0b013e3181bddf70.

PMID:
19809387
17.

Comparison of intermittent versus continuous vancomycin infusion for the treatment of late-onset sepsis in preterm infants.

Demirel B, İmamoglu E, Gursoy T, Demirel U, Topçuoglu S, Karatekin G, Ovali F.

J Neonatal Perinatal Med. 2015;8(2):149-55. doi: 10.3233/NPM-15814103.

PMID:
26410440
18.

Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion.

Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Müller M, Tschernko E.

Anesthesiology. 2009 Aug;111(2):356-65. doi: 10.1097/ALN.0b013e3181a97272.

PMID:
19602966
19.

Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study.

Bhatt-Mehta V, Schumacher RE, Faix RG, Leady M, Brenner T.

Pediatrics. 1999 Apr;103(4):e48.

PMID:
10103340
20.

[Therapeutic monitoring of vancomycin in routine clinical practice].

Kacířová I, Grundmann M.

Vnitr Lek. 2014 Oct;60(10):846-51. Review. Czech.

PMID:
25382007

Supplemental Content

Support Center